Singular Genomics Systems (NASDAQ:OMIC) Price Target Cut to $6.50

Singular Genomics Systems (NASDAQ:OMIC) had its price target decreased by investment analysts at The Goldman Sachs Group from $22.50 to $6.50 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has a “neutral” rating on the stock. The Goldman Sachs Group’s price target would indicate a potential downside of 14.70% from the company’s current price.

Separately, UBS Group raised their price target on Singular Genomics Systems from $12.00 to $15.00 and gave the stock a “neutral” rating in a report on Wednesday, March 20th.

Singular Genomics Systems Stock Performance

NASDAQ:OMIC opened at $7.62 on Tuesday. The company has a quick ratio of 9.54, a current ratio of 10.35 and a debt-to-equity ratio of 0.05. The business’s 50 day moving average is $10.54 and its two-hundred day moving average is $13.14. Singular Genomics Systems has a 52 week low of $7.50 and a 52 week high of $31.50. The company has a market cap of $18.82 million, a PE ratio of -0.19 and a beta of 1.35.

Singular Genomics Systems (NASDAQ:OMIC) last released its earnings results on Tuesday, May 14th. The company reported ($10.20) EPS for the quarter. The firm had revenue of $0.44 million for the quarter, compared to the consensus estimate of $0.50 million. Singular Genomics Systems had a negative return on equity of 51.10% and a negative net margin of 3,863.90%.

Institutional Trading of Singular Genomics Systems

A hedge fund recently raised its stake in Singular Genomics Systems stock. Weil Company Inc. boosted its holdings in Singular Genomics Systems, Inc. (NASDAQ:OMIC) by 16.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 138,202 shares of the company’s stock after acquiring an additional 20,000 shares during the quarter. Weil Company Inc. owned 0.19% of Singular Genomics Systems worth $64,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 65.80% of the company’s stock.

About Singular Genomics Systems

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.